Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination With Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With Diffuse Large B-Cell Lymphoma

Next Previous
Trial Profile

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination With Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With Diffuse Large B-Cell Lymphoma

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Polatuzumab vedotin (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; T-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms POLARIX
  • Sponsors Chugai Pharmaceutical; Genentech; Roche

Most Recent Events

  • 22 Jul 2025 According to a Roche Canada media release, Polivy received the first marketing authorization in Canada on July 9, 2020 from Health Canada, and on July 2, 2025, Quebec approved it for public reimbursement for first-line treatment of DLBCL, and this work of moving Polivy from regulatory approval through to public access continues with the other provinces and territories.
  • 08 Dec 2024 According to a Genentech media release, data from this study were presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, December 7-10, 2024 in San Diego, California.
  • 08 Dec 2024 Results presented in a Genentech Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top